microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches

Parkinson’s disease (PD) is the most prevalent central nervous system (CNS) movement disorder and the second most common neurodegenerative disease overall. PD is characterized by the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) within the midbrain,...

Full description

Bibliographic Details
Main Authors: Loredana Leggio, Silvia Vivarelli, Francesca L’Episcopo, Cataldo Tirolo, Salvo Caniglia, Nunzio Testa, Bianca Marchetti, Nunzio Iraci
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/18/12/2698
id doaj-87491235af9f49ee8d44aa8b0196fa2b
record_format Article
spelling doaj-87491235af9f49ee8d44aa8b0196fa2b2020-11-25T01:42:02ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-12-011812269810.3390/ijms18122698ijms18122698microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic ApproachesLoredana Leggio0Silvia Vivarelli1Francesca L’Episcopo2Cataldo Tirolo3Salvo Caniglia4Nunzio Testa5Bianca Marchetti6Nunzio Iraci7Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyParkinson’s disease (PD) is the most prevalent central nervous system (CNS) movement disorder and the second most common neurodegenerative disease overall. PD is characterized by the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) within the midbrain, accumulation of alpha-synuclein (α-SYN) in Lewy bodies and neurites and excessive neuroinflammation. The neurodegenerative processes typically begin decades before the appearance of clinical symptoms. Therefore, the diagnosis is achievable only when the majority of the relevant DAergic neurons have already died and for that reason available treatments are only palliative at best. The causes and mechanism(s) of this devastating disease are ill-defined but complex interactions between genetic susceptibility and environmental factors are considered major contributors to the etiology of PD. In addition to the role of classical gene mutations in PD, the importance of regulatory elements modulating gene expression has been increasingly recognized. One example is the critical role played by microRNAs (miRNAs) in the development and homeostasis of distinct populations of neurons within the CNS and, in particular, in the context of PD. Recent reports demonstrate how distinct miRNAs are involved in the regulation of PD genes, whereas profiling approaches are unveiling variations in the abundance of certain miRNAs possibly relevant either to the onset or to the progression of the disease. In this review, we provide an overview of the miRNAs recently found to be implicated in PD etiology, with particular focus on their potential relevance as PD biomarkers, as well as their possible use in PD targeted therapy.https://www.mdpi.com/1422-0067/18/12/2698parkinson’s diseasemicroRNAsbiomarkersexosomesneuroprotective therapies
collection DOAJ
language English
format Article
sources DOAJ
author Loredana Leggio
Silvia Vivarelli
Francesca L’Episcopo
Cataldo Tirolo
Salvo Caniglia
Nunzio Testa
Bianca Marchetti
Nunzio Iraci
spellingShingle Loredana Leggio
Silvia Vivarelli
Francesca L’Episcopo
Cataldo Tirolo
Salvo Caniglia
Nunzio Testa
Bianca Marchetti
Nunzio Iraci
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
International Journal of Molecular Sciences
parkinson’s disease
microRNAs
biomarkers
exosomes
neuroprotective therapies
author_facet Loredana Leggio
Silvia Vivarelli
Francesca L’Episcopo
Cataldo Tirolo
Salvo Caniglia
Nunzio Testa
Bianca Marchetti
Nunzio Iraci
author_sort Loredana Leggio
title microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
title_short microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
title_full microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
title_fullStr microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
title_full_unstemmed microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
title_sort micrornas in parkinson’s disease: from pathogenesis to novel diagnostic and therapeutic approaches
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2017-12-01
description Parkinson’s disease (PD) is the most prevalent central nervous system (CNS) movement disorder and the second most common neurodegenerative disease overall. PD is characterized by the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) within the midbrain, accumulation of alpha-synuclein (α-SYN) in Lewy bodies and neurites and excessive neuroinflammation. The neurodegenerative processes typically begin decades before the appearance of clinical symptoms. Therefore, the diagnosis is achievable only when the majority of the relevant DAergic neurons have already died and for that reason available treatments are only palliative at best. The causes and mechanism(s) of this devastating disease are ill-defined but complex interactions between genetic susceptibility and environmental factors are considered major contributors to the etiology of PD. In addition to the role of classical gene mutations in PD, the importance of regulatory elements modulating gene expression has been increasingly recognized. One example is the critical role played by microRNAs (miRNAs) in the development and homeostasis of distinct populations of neurons within the CNS and, in particular, in the context of PD. Recent reports demonstrate how distinct miRNAs are involved in the regulation of PD genes, whereas profiling approaches are unveiling variations in the abundance of certain miRNAs possibly relevant either to the onset or to the progression of the disease. In this review, we provide an overview of the miRNAs recently found to be implicated in PD etiology, with particular focus on their potential relevance as PD biomarkers, as well as their possible use in PD targeted therapy.
topic parkinson’s disease
microRNAs
biomarkers
exosomes
neuroprotective therapies
url https://www.mdpi.com/1422-0067/18/12/2698
work_keys_str_mv AT loredanaleggio micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT silviavivarelli micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT francescalepiscopo micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT cataldotirolo micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT salvocaniglia micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT nunziotesta micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT biancamarchetti micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
AT nunzioiraci micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches
_version_ 1725038244768251904